- Home
- OPHC vs TCRX Comparison
OPHC vs TCRX Comparison
Compare OPHC & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPHC | TCRX |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 75.1M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OPHC | TCRX |
|---|---|---|
| Price | $5.54 | $0.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.50 | ★ $7.00 |
| AVG Volume (30 Days) | 20.7K | ★ 442.5K |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | $17,095.98 | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | $27.50 | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $3.91 | $0.88 |
| 52 Week High | $5.64 | $2.57 |
Technical Indicators
Market Signals| Indicator | OPHC | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 35.91 |
| Support Level | $5.40 | $0.91 |
| Resistance Level | $5.60 | $1.16 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 78.57 | 6.84 |
Price Performance
Historical ComparisonAbout OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.